Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Q3 2025 value amounting to 2720.76%.

  • Entrada Therapeutics' EBITDA Margin fell 26557000.0% to 2720.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 168.74%, marking a year-over-year decrease of 1949500.0%. This contributed to the annual value of 31.02% for FY2024, which is 344600.0% up from last year.
  • Per Entrada Therapeutics' latest filing, its EBITDA Margin stood at 2720.76% for Q3 2025, which was down 26557000.0% from 2212.31% recorded in Q2 2025.
  • Entrada Therapeutics' 5-year EBITDA Margin high stood at 82.25% for Q3 2023, and its period low was 2720.76% during Q3 2025.
  • For the 3-year period, Entrada Therapeutics' EBITDA Margin averaged around 462.48%, with its median value being 21.16% (2023).
  • In the last 5 years, Entrada Therapeutics' EBITDA Margin surged by 2027200bps in 2024 and then crashed by -26557000bps in 2025.
  • Quarter analysis of 3 years shows Entrada Therapeutics' EBITDA Margin stood at 21.16% in 2023, then soared by 101bps to 0.31% in 2024, then tumbled by -877262bps to 2720.76% in 2025.
  • Its last three reported values are 2720.76% in Q3 2025, 2212.31% for Q2 2025, and 82.06% during Q1 2025.